17:02 EST Mirum Pharmaceuticals (MIRM) sees FY25 product sales of $500M-$510M, consensus $506.3M
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MIRM:
- MIRM Upcoming Earnings Report: What to Expect?
- Mirum Pharmaceuticals Advances in Fragile X Syndrome Treatment Study
- Mirum Pharmaceuticals’ Volixibat Study: A Potential Breakthrough for PBC Itching
- Mirum Pharmaceuticals Advances Phase 3 Study on Maralixibat for Cholestatic Pruritus
- Mirum Pharmaceuticals’ LEAP-US Study: A Long-Term Look at Livmarli’s Impact